The reiteration of an Outperform rating by Wedbush analyst Robert Driscoll indicates a positive outlook for IGM Biosciences. The maintained $37 price target suggests that the stock has potential for growth in the short term. This news is highly relevant and important for investors in IGMS, and the confidence in the analysis is high due to the analyst's expertise.